Grifols | GRFS - Current Liabilities


Grifols reported EUR2.37B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 595K 218K Mar/2026
Arca Biopharma USD 22.97M 6.34M Jun/2026
aTyr Pharma USD 11.4M 303K Jun/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 12.38M 621K Jun/2026
Capricor Therapeutics USD 32.96M 676K Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Grifols EUR 2.37B 156.97M Dec/2025
Immunic USD 38.36M 7.74M Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024